Laurén I

A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T proliferation and anti-tumor immunity in mice.

Mebrahtu A, Laurén I, Veerman R, ..., Rockberg J, Mangsbo S

Nat Commun 15 (1) 9542 [2024-11-05; online 2024-11-05]

Affinity Proteomics Uppsala [Service] Drug Discovery and Development (DDD) [Service]

An Adaptable Antibody‐Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies

Eltahir M, Laurén I, Lord M, ..., Persson H, Mangsbo SM

Advanced Therapeutics 5 (7) 2200008 [2022-07-00; online 2022-06-14]

Drug Discovery and Development (DDD) [Collaborative]

Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology.

Laurén I, Havervall S, Ng H, ..., Thålin C, Mangsbo S

Immun Inflamm Dis 10 (4) e595 [2022-04-00; online 2022-03-30]

Autoimmunity and Serology Profiling [Collaborative]